

June 2026

MEDPACE
Clinical Pharmacology

HM-UCN2-101 MAD Cohort 1

Study Inpatient dates:

Jun 17-21, 2026

Sep 02-06, 2026

Study Outpatient dates:

Jun 25, 2026

Jul 02, 09, 16, 23, 30, 2026

Aug 06, 13, 20, 27, 2026

Sep 10, 2026 and Oct 08, 2026

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding.
- Abstain from egg donation **during the study** and abstain from sperm donation **during the study and for 90 days after final dose of study drug (Day 78)**.
- Must not have any major surgery **within 6 months prior to Screening**.
- Avoid donation of blood **within 60 days prior to first dose of study drug (Day 1)** and avoid donation of blood or plasma **throughout the study**.
- Must not have a history of drug abuse, positive drug test, or frequent use of marijuana or other THC products **within 1 year prior to Screening**.
- Must not have a history of alcohol abuse **within 1 year prior to Screening** (drinking more than 14 standard units per week).
- Must not smoke more than 10 cigarettes per day (or nicotine equivalent) **at the time of Screening or plan to use during the study**.
- Abstain from smoking and tobacco-containing products **24 hours prior to Admission (Day -1) and throughout the study**.
- Abstain from caffeine, alcohol, and tobacco for **24 hours prior to each admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.
- Abstain from strenuous exercise **24 hours prior to each admission (Days -1 and 77) and outpatient visits with blood collection for clinical lab tests (Days 8, 15, 29, 57, 85, and 113)**.
- Must not use any investigational product **within 30 days or 5 half-lives (whichever is longer) prior to Screening**.
- Must not initiate treatment with any new prescription medications **from the time of Screening until the end of study** unless agreed to by the study physician.
- Avoid use of any anti-obesity medications, nutritional supplements or over-the-counter products for weight loss, any product or medication known or suspected to cause weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, and mood stabilizers), and use of skeletal muscle anabolic agents in any form, such as medications, hormones, over-the-counter products, and nutritional supplements (other than protein) that were labeled as muscle anabolic agents **within 3 months prior to Screening**.
- Avoid initiation of hormone replacement therapy **within 2 months of Screening**.
- Avoid use of any lipid-lowering agents, unless on stable dose for **at least 3 months prior to Screening**.
- Avoid use of any antihypertensive medications, any weight control treatment, e.g., GLP-1 receptor agonist related study (prescribed mono or dual agonist therapies or any GLP-1 receptor agonist mono or combination therapy provided during a clinical study such as triple agonist or other combinations), and use of any vasodilators (including PDE5 inhibitors) **within 3 months prior to Screening**.
- Fast overnight for **at least 8 hours (no foods or liquids other than water) prior to Admission (Day -1) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.

Reminder: Breath alcohol & urine drug test at each Admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113). COVID-19 rapid antigen test at each Admission (Days -1 and 77) only.

***Payment to occur within 48 hours after payment visit day**

***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	2	3	4	5 Screening MRI/DEXA Window Closes*	6
7	8	9	10	11	12	13
14	15	16 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin overnight fast	17 Day -1 Admission	18 Day 1 Dose	19 Day 2 Inpatient	20 Day 3 Inpatient
21 Day 4 Discharge Payment 1*	22	23	24 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin overnight fast	25 Day 8 OPV	26	27
28	29	30				

July 2026

MEDPACE Clinical Pharmacology

HM-UCN2-101 MAD Cohort 1

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin overnight fast	2 Day 15 OPV	3	4 Independence Day
5	6	7	8 Begin caffeine, alcohol, and tobacco restrictions Begin overnight fast	9 Day 22 OPV	10	11
12	13	14	15 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin overnight fast	16 Day 29 OPV Payment 2*	17	18
19	20	21	22 Begin caffeine, alcohol, and tobacco restrictions Begin overnight fast	23 Day 36 OPV	24	25
26	27	28	29 Begin caffeine, alcohol, and tobacco restrictions Begin overnight fast	30 Day 43 OPV	31	

Study Inpatient dates:

Jun 17-21, 2026

Sep 02-06, 2026

Study Outpatient dates:

Jun 25, 2026

Jul 02, 09, 16, 23, 30, 2026

Aug 06, 13, 20, 27, 2026

Sep 10, 2026 and Oct 08, 2026

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding.
- Abstain from egg donation **during the study** and abstain from sperm donation **during the study and for 90 days after final dose of study drug (Day 78)**.
- Must not have any major surgery **within 6 months prior to Screening**.
- Avoid donation of blood **within 60 days prior to first dose of study drug (Day 1)** and avoid donation of blood or plasma **throughout the study**.
- Must not have a history of drug abuse, positive drug test, or frequent use of marijuana or other THC products **within 1 year prior to Screening**.
- Must not have a history of alcohol abuse **within 1 year prior to Screening** (drinking more than 14 standard units per week).
- Must not smoke more than 10 cigarettes per day (or nicotine equivalent) **at the time of Screening or plan to use during the study**.
- Abstain from smoking and tobacco-containing products **24 hours prior to Admission (Day -1)** and **throughout the study**.
- Abstain from caffeine, alcohol, and tobacco for **24 hours prior to each admission (Days -1 and 77)** and **all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.
- Abstain from strenuous exercise **24 hours prior to each admission (Days -1 and 77)** and **outpatient visits with blood collection for clinical lab tests (Days 8, 15, 29, 57, 85, and 113)**.
- Must not use any investigational product **within 30 days or 5 half-lives (whichever is longer) prior to Screening**.
- Must not initiate treatment with any new prescription medications **from the time of Screening until the end of study** unless agreed to by the study physician.
- Avoid use of any anti-obesity medications, nutritional supplements or over-the-counter products for weight loss, any product or medication known or suspected to cause weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, and mood stabilizers), and use of skeletal muscle anabolic agents in any form, such as medications, hormones, over-the-counter products, and nutritional supplements (other than protein) that were labeled as muscle anabolic agents **within 3 months prior to Screening**.
- Avoid initiation of hormone replacement therapy **within 2 months of Screening**.
- Avoid use of any lipid-lowering agents, unless on stable dose for **at least 3 months prior to Screening**.
- Avoid use of any antihypertensive medications, any weight control treatment, e.g., GLP-1 receptor agonist related study (prescribed mono or dual agonist therapies or any GLP-1 receptor agonist mono or combination therapy provided during a clinical study such as triple agonist or other combinations), and use of any vasodilators (including PDE5 inhibitors) **within 3 months prior to Screening**.
- Fast overnight for **at least 8 hours (no foods or liquids other than water) prior to Admission (Day -1)** and **all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.

Reminder: Breath alcohol & urine drug test at each Admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113). COVID-19 rapid antigen test at each Admission (Days -1 and 77) only.

***Payment to occur within 48 hours after payment visit day**

***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

August 2026

MEDPACE Clinical Pharmacology

HM-UCN2-101 MAD Cohort 1

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						1
2	3	4	5 Begin caffeine, alcohol, and tobacco restrictions Begin overnight fast	6 Day 50 OPV	7	8
9	10	11	12 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin overnight fast	13 Day 57 OPV	14	15
16	17	18	19 Begin caffeine, alcohol, and tobacco restrictions Begin overnight fast	20 Day 64 OPV	21	22
23	24	25	26 Begin caffeine, alcohol, and tobacco restrictions Begin overnight fast	27 Day 71 OPV Payment 3*	28	29
30	31					

Study Inpatient dates:

Jun 17-21, 2026

Sep 02-06, 2026

Study Outpatient dates:

Jun 25, 2026

Jul 02, 09, 16, 23, 30, 2026

Aug 06, 13, 20, 27, 2026

Sep 10, 2026 and Oct 08, 2026

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding.
- Abstain from egg donation **during the study** and abstain from sperm donation **during the study and for 90 days after final dose of study drug (Day 78)**.
- Must not have any major surgery **within 6 months prior to Screening**.
- Avoid donation of blood **within 60 days prior to first dose of study drug (Day 1)** and avoid donation of blood or plasma **throughout the study**.
- Must not have a history of drug abuse, positive drug test, or frequent use of marijuana or other THC products **within 1 year prior to Screening**.
- Must not have a history of alcohol abuse **within 1 year prior to Screening** (drinking more than 14 standard units per week).
- Must not smoke more than 10 cigarettes per day (or nicotine equivalent) **at the time of Screening or plan to use during the study**.
- Abstain from smoking and tobacco-containing products **24 hours prior to Admission (Day -1) and throughout the study**.
- Abstain from caffeine, alcohol, and tobacco for **24 hours prior to each admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.
- Abstain from strenuous exercise **24 hours prior to each admission (Days -1 and 77) and outpatient visits with blood collection for clinical lab tests (Days 8, 15, 29, 57, 85, and 113)**.
- Must not use any investigational product **within 30 days or 5 half-lives (whichever is longer) prior to Screening**.
- Must not initiate treatment with any new prescription medications **from the time of Screening until the end of study** unless agreed to by the study physician.
- Avoid use of any anti-obesity medications, nutritional supplements or over-the-counter products for weight loss, any product or medication known or suspected to cause weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, and mood stabilizers), and use of skeletal muscle anabolic agents in any form, such as medications, hormones, over-the-counter products, and nutritional supplements (other than protein) that were labeled as muscle anabolic agents **within 3 months prior to Screening**.
- Avoid initiation of hormone replacement therapy **within 2 months of Screening**.
- Avoid use of any lipid-lowering agents, unless on stable dose for **at least 3 months prior to Screening**.
- Avoid use of any antihypertensive medications, any weight control treatment, e.g., GLP-1 receptor agonist related study (prescribed mono or dual agonist therapies or any GLP-1 receptor agonist mono or combination therapy provided during a clinical study such as triple agonist or other combinations), and use of any vasodilators (including PDE5 inhibitors) **within 3 months prior to Screening**.
- Fast overnight for **at least 8 hours (no foods or liquids other than water) prior to Admission (Day -1) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.

Reminder: Breath alcohol & urine drug test at each Admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113). COVID-19 rapid antigen test at each Admission (Days -1 and 77) only.

***Payment to occur within 48 hours after payment visit day**

***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

September 2026

MEDPACE Clinical Pharmacology

HM-UCN2-101 MAD Cohort 1

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		1 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions	2 Day 77 Admission	3 Day 78 Dose	4 Day 79 Inpatient	5 Day 80 Inpatient
6 Day 81 Discharge	7 Labor Day	8 D85 MRI/DEXA Window Opens*	9 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin overnight fast	10 Day 85 OPV	11 D85 MRI/DEXA Window Closes*	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30			

Study Inpatient dates:

Jun 17-21, 2026

Sep 02-06, 2026

Study Outpatient dates:

Jun 25, 2026

Jul 02, 09, 16, 23, 30, 2026

Aug 06, 13, 20, 27, 2026

Sep 10, 2026 and Oct 08, 2026

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding.
- Abstain from egg donation **during the study** and abstain from sperm donation **during the study and for 90 days after final dose of study drug (Day 78)**.
- Must not have any major surgery **within 6 months prior to Screening**.
- Avoid donation of blood **within 60 days prior to first dose of study drug (Day 1)** and avoid donation of blood or plasma **throughout the study**.
- Must not have a history of drug abuse, positive drug test, or frequent use of marijuana or other THC products **within 1 year prior to Screening**.
- Must not have a history of alcohol abuse **within 1 year prior to Screening** (drinking more than 14 standard units per week).
- Must not smoke more than 10 cigarettes per day (or nicotine equivalent) **at the time of Screening or plan to use during the study**.
- Abstain from smoking and tobacco-containing products **24 hours prior to Admission (Day -1) and throughout the study**.
- Abstain from caffeine, alcohol, and tobacco for **24 hours prior to each admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.
- Abstain from strenuous exercise **24 hours prior to each admission (Days -1 and 77) and outpatient visits with blood collection for clinical lab tests (Days 8, 15, 29, 57, 85, and 113)**.
- Must not use any investigational product **within 30 days or 5 half-lives (whichever is longer) prior to Screening**.
- Must not initiate treatment with any new prescription medications **from the time of Screening until the end of study** unless agreed to by the study physician.
- Avoid use of any anti-obesity medications, nutritional supplements or over-the-counter products for weight loss, any product or medication known or suspected to cause weight gain (e.g., tricyclic anti-depressants, atypical antipsychotics, and mood stabilizers), and use of skeletal muscle anabolic agents in any form, such as medications, hormones, over-the-counter products, and nutritional supplements (other than protein) that were labeled as muscle anabolic agents **within 3 months prior to Screening**.
- Avoid initiation of hormone replacement therapy **within 2 months of Screening**.
- Avoid use of any lipid-lowering agents, unless on stable dose for **at least 3 months prior to Screening**.
- Avoid use of any antihypertensive medications, any weight control treatment, e.g., GLP-1 receptor agonist related study (prescribed mono or dual agonist therapies or any GLP-1 receptor agonist mono or combination therapy provided during a clinical study such as triple agonist or other combinations), and use of any vasodilators (including PDE5 inhibitors) **within 3 months prior to Screening**.
- Fast overnight for **at least 8 hours (no foods or liquids other than water) prior to Admission (Day -1) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.

Reminder: Breath alcohol & urine drug test at each Admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113). COVID-19 rapid antigen test at each Admission (Days -1 and 77) only.

***Payment to occur within 48 hours after payment visit day**

***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

October 2026

MEDPACE
Clinical Pharmacology

HM-UCN2-101 MAD Cohort 1

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5	6	7 Begin caffeine, alcohol, tobacco, and strenuous exercise restrictions Begin over-night fast	8 Day 113 OPV (EOS) Payment 4*	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	23
25	26	27	28	29	30	31

Study Inpatient dates:

Jun 17-21, 2026

Sep 02-06, 2026

Study Outpatient dates:

Jun 25, 2026

Jul 02, 09, 16, 23, 30, 2026

Aug 06, 13, 20, 27, 2026

Sep 10, 2026 and Oct 08, 2026

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding.
- Abstain from egg donation **during the study** and abstain from sperm donation **during the study and for 90 days after final dose of study drug (Day 78)**.
- Must not have any major surgery **within 6 months prior to Screening**.
- Avoid donation of blood **within 60 days prior to first dose of study drug (Day 1)** and avoid donation of blood or plasma **throughout the study**.
- Must not have a history of drug abuse, positive drug test, or frequent use of marijuana or other THC products **within 1 year prior to Screening**.
- Must not have a history of alcohol abuse **within 1 year prior to Screening** (drinking more than 14 standard units per week).
- Must not smoke more than 10 cigarettes per day (or nicotine equivalent) **at the time of Screening or plan to use during the study**.
- Abstain from smoking and tobacco-containing products **24 hours prior to Admission (Day -1) and throughout the study**.
- Abstain from caffeine, alcohol, and tobacco for **24 hours prior to each admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.
- Abstain from strenuous exercise **24 hours prior to each admission (Days -1 and 77) and outpatient visits with blood collection for clinical lab tests (Days 8, 15, 29, 57, 85, and 113)**.
- Must not use any investigational product **within 30 days or 5 half-lives (whichever is longer) prior to Screening**.
- Must not initiate treatment with any new prescription medications **from the time of Screening until the end of study** unless agreed to by the study physician.
- Avoid use of any anti-obesity medications, nutritional supplements or over-the-counter products for weight loss, any product or medication known or suspected to cause weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, and mood stabilizers), and use of skeletal muscle anabolic agents in any form, such as medications, hormones, over-the-counter products, and nutritional supplements (other than protein) that were labeled as muscle anabolic agents **within 3 months prior to Screening**.
- Avoid initiation of hormone replacement therapy **within 2 months of Screening**.
- Avoid use of any lipid-lowering agents, unless on stable dose for **at least 3 months prior to Screening**.
- Avoid use of any antihypertensive medications, any weight control treatment, e.g., GLP-1 receptor agonist related study (prescribed mono or dual agonist therapies or any GLP-1 receptor agonist mono or combination therapy provided during a clinical study such as triple agonist or other combinations), and use of any vasodilators (including PDE5 inhibitors) **within 3 months prior to Screening**.
- Fast overnight for **at least 8 hours (no foods or liquids other than water) prior to Admission (Day -1) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113)**.

Reminder: Breath alcohol & urine drug test at each Admission (Days -1 and 77) and all outpatient visits (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85, and 113). COVID-19 rapid antigen test at each Admission (Days -1 and 77) only.

***Payment to occur within 48 hours after payment visit day**

***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**